search
Back to results

DaVitri: Semi-Automated Vitrificacion Clinical Study (DaVitri)

Primary Purpose

Fertility Issues

Status
Recruiting
Phase
Not Applicable
Locations
Argentina
Study Type
Interventional
Intervention
Manual Vitrification
Automated Vitrification
Sponsored by
Overture Life
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Fertility Issues focused on measuring Vitrification

Eligibility Criteria

30 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Donors will be selected according to the clinic's usual inclusion criteria in terms of infectious diseases, genetic diseases, karyotype, etc. Exclusion Criteria: BMI<18.5 or BMI >25 Implantation failure Abnormal ovulation cycle Endometrial thickness > 7mm

Sites / Locations

  • WeFIV Buenos AiresRecruiting
  • Halitus Instituto Médico

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Manual

Automated

Arm Description

Oocytes will be prepared for vitrification using the manual protocol

Oocytes will be prepared for vitrification using Davitri device

Outcomes

Primary Outcome Measures

Thaw survival rates of oocytes
Number of valid oocytes/numbers of randomized oocytes

Secondary Outcome Measures

Blastocyst formation rate
Number of blastocysts at day 5 or 6/number of fertilized oocytes

Full Information

First Posted
November 2, 2022
Last Updated
July 28, 2023
Sponsor
Overture Life
search

1. Study Identification

Unique Protocol Identification Number
NCT05607771
Brief Title
DaVitri: Semi-Automated Vitrificacion Clinical Study
Acronym
DaVitri
Official Title
Paired Non-inferiority Study Comparing Overture Semi-Automated Vitrification System ("DaVitri") to Standard Manual Process
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 20, 2023 (Actual)
Primary Completion Date
July 30, 2024 (Anticipated)
Study Completion Date
July 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Overture Life

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of this clinical study is to demonstrate the non-inferiority of the semi automated device (DaVitri) developed by Overture Life in the preparation procedures for vitrification of human samples.
Detailed Description
Vitrification is a manual technique that is routinely used in assisted reproduction clinics for the cryopreservation of oocytes and embryos in liquid nitrogen at -196oC. There are different methods of vitrification, the most used being the Cryotop of Kitazato. This is a manual process that requires precision and experience to achieve a good result. For this reason, the correct execution of the technique is considered key in in vitro fertilization (IVF) treatments, as it can favor the preservation of fertility and optimize clinical results. The purpose of the study is to validate the viability of the semi automated vitrification process, to obtain survival rates similar to or superior to manual processes, and also the capacity to provide greater reproducibility in the results. The semi automatic exchange of vitrification fluids in human oocytes is as efficient as the manual procedure, in terms of survival (85-90%), but with significantly lower variability between technicians and between centers (95% reproducibility), as well as reduced manual processing times. The initial hypothesis is that semi automated vitrification equals or improves the manual technique, thus introducing a new standardized protocol for clinical use.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fertility Issues
Keywords
Vitrification

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Manual
Arm Type
Experimental
Arm Description
Oocytes will be prepared for vitrification using the manual protocol
Arm Title
Automated
Arm Type
Experimental
Arm Description
Oocytes will be prepared for vitrification using Davitri device
Intervention Type
Device
Intervention Name(s)
Manual Vitrification
Intervention Description
Oocytes will be prepared for vitrification using the manual protocol
Intervention Type
Device
Intervention Name(s)
Automated Vitrification
Intervention Description
Oocytes will be prepared for vitrification using the DaVitri device
Primary Outcome Measure Information:
Title
Thaw survival rates of oocytes
Description
Number of valid oocytes/numbers of randomized oocytes
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Blastocyst formation rate
Description
Number of blastocysts at day 5 or 6/number of fertilized oocytes
Time Frame
Day 5

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Donors will be selected according to the clinic's usual inclusion criteria in terms of infectious diseases, genetic diseases, karyotype, etc. Exclusion Criteria: BMI<18.5 or BMI >25 Implantation failure Abnormal ovulation cycle Endometrial thickness > 7mm
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernando Neuspiller, MD
Organizational Affiliation
WeFiv
Official's Role
Principal Investigator
Facility Information:
Facility Name
WeFIV Buenos Aires
City
Buenos Aires
ZIP/Postal Code
C1428ARP
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fernando Neuspiller
Phone
0810-220-2200
Email
Fernando.Neuspiller@wefiv.com
Facility Name
Halitus Instituto Médico
City
Buenos Aires
Country
Argentina
Individual Site Status
Active, not recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

DaVitri: Semi-Automated Vitrificacion Clinical Study

We'll reach out to this number within 24 hrs